DR Congo Ervebo Vaccine Bundibugyo Outbreak: 70,000 Doses Allocated

• The Democratic Republic of Congo will receive 70,000 doses of the Ervebo vaccine from the UN's International Vaccine Coordination Group to combat the Bundibugyo Ebola strain.
• While the Ervebo vaccine was developed for the Zaire ebolavirus, its efficacy against the Bundibugyo strain is uncertain, prompting a clinical trial using 20,000 doses, with 50,000 doses allocated to health workers.
• The current Ebola outbreak, declared on May 15, has become the deadliest in the DRC's history, with 2,325 deaths and 5,021 cases reported.
• Ongoing conflict in eastern DRC, involving the UN-sanctioned M23 armed group, severely hinders Ebola response efforts by blocking medical access and displacing populations.
• The M23 armed group has claimed to establish its own Ebola response administration and suspended transport to affected government zones, despite being condemned for atrocities.

This involvement by the M23 group is particularly fraught, given that the United Nations has sanctioned and strongly condemned the militia for committing severe atrocities against civilians, including forced recruitment, mass killings, and sexual violence, as documented by numerous reports, investigations, and testimonies.

The Democratic Republic of Congo (DRC) is set to receive 70,000 doses of the Ervebo vaccine, a critical intervention coordinated by the UN's International Vaccine Coordination Group (ICG), aimed at safeguarding communities on the front lines of the Ebola virus disease. This allocation follows a request from the government in Kinshasa to access the global Ebola vaccine stockpile. While the Ervebo vaccine was originally developed to combat the Zaire ebolavirus, responsible for the deadliest recorded outbreak in West Africa between 2014 and 2016, its efficacy against the current Bundibugyo strain of Ebola remains unconfirmed.

The World Health Organization (WHO) acknowledged the allocation on Thursday but emphasized the uncertainty surrounding the Ervebo vaccine's effectiveness against the Bundibugyo strain. Preliminary laboratory and animal studies suggest it might offer some level of protection, prompting the decision to conduct a clinical trial. This trial is crucial for gathering new evidence that will inform policymakers on the future application of the Ervebo vaccine. Given the rapid progression of the Bundibugyo outbreak, the ICG has designated 20,000 doses specifically for this clinical trial within the DRC, with the remaining 50,000 doses earmarked for health workers. Clinical trials have indicated that severe side effects from the Ervebo vaccine are exceedingly rare, and some residents in affected regions may receive the vaccine outside the trial framework. WHO Director-General Tedros Adhanom Ghebreyesus lauded the vaccine release on Thursday, characterizing it as a significant demonstration of global solidarity.

The urgency of this vaccine deployment is underscored by the escalating severity of the Democratic Republic of Congo Ebola outbreak, which was first declared on May 15. Earlier this week, the outbreak tragically surpassed all previous records, becoming the nation's deadliest with 2,325 fatalities. Although local authorities had not updated the death toll since Monday, the total number of confirmed cases had climbed to 5,021 by Wednesday. The human cost extends to healthcare professionals, with over 160 health workers having contracted the virus and 40 succumbing to the disease, as reported by UN Senior Ebola Coordinator Julien Harneis on Thursday.

Compounding the public health emergency is the persistent conflict in eastern DRC, where the Congolese Government is engaged in hostilities with the Rwanda-backed M23 armed group, alongside numerous other militant factions. This ongoing instability severely impedes efforts to contain the virus, as medical teams are frequently prevented from accessing conflict-affected areas. The violence has led to the destruction or forced closure of vital health centers and the displacement of thousands of civilians, rendering crucial public health measures like contact-tracing and safe burials almost impossible.

Adding a complex layer to the response, the M23 armed group has publicly asserted its capacity to manage an independent Ebola response, distinct from Kinshasa's efforts. The group claims to have established its own health administration, which reportedly oversees laboratories and conducts disease surveillance. Furthermore, M23 announced on Thursday its decision to suspend shared taxi and boat services to and from government-controlled zones impacted by Ebola, ostensibly to prevent the virus's spread into territories under its command. This involvement by the M23 group is particularly fraught, given that the United Nations has sanctioned and strongly condemned the militia for committing severe atrocities against civilians, including forced recruitment, mass killings, and sexual violence, as documented by numerous reports, investigations, and testimonies.

The ICG, which plays a pivotal role in managing and coordinating the provision of emergency vaccine supplies and antibiotics globally during major outbreaks, is central to this latest effort. Its prior engagements in the DRC include allocating 56,000 Ervebo vaccine doses to address multiple Ebola outbreaks between 2021 and July 2026. The recent allocation was met with optimism by UN Senior Ebola Coordinator Julien Harneis, who took to X (formerly Twitter) to commend the ICG's decision. Harneis expressed that this vaccine distribution "gives hope for everyone in the affected areas and in particular for frontline health workers," underscoring the critical role of international cooperation in confronting such complex health crises.

Compliance officers and legal teams advising clients operating in the DRC, particularly in conflict zones, should note the involvement of the UN-sanctioned M23 armed group in humanitarian efforts. This necessitates enhanced due diligence to ensure compliance with international sanctions regimes and to mitigate risks associated with engaging, even indirectly, with entities accused of atrocities.

Source: Original reporting via UN